Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

Abstract Background Atherogenic dyslipidemia (AD), characterized by increased concentrations of apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 diabetes mellitus (T2DM). Non-high-density lipoprotein cholesterol (non-HDL-C), cholesterol transported by apolipo...

Full description

Bibliographic Details
Main Authors: Alberto J. Lorenzatti, Maria Laura Monsalvo, J. Antonio G. López, Huei Wang, Robert S. Rosenson
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Cardiovascular Diabetology
Subjects:
Atherogenic dyslipidemia
Cardiovascular disease
Diabetes mellitus
Evolocumab
Lipid-lowering therapy
Lipoproteins
Online Access:https://doi.org/10.1186/s12933-021-01287-6

Similar Items

Similar Items